Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥11.57 Million ≈ $1.69 Million USD) by net assets (CN¥2.26 Billion ≈ $330.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Hubei Biocause Heilen Pharmaceutical Co. to measure how many days the company can operate on defensive assets alone.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Neogen Chemicals Limited
NSE:NEOGEN
|
-0.302x |
|
Australian Agricultural Company Ltd
AU:AAC
|
0.001x |
|
Vibhavadi Medical Center Public Company Limited
BK:VIBHA
|
0.043x |
|
Sincere Navigation Corp
TW:2605
|
0.034x |
|
Everspin Technologies Inc
NASDAQ:MRAM
|
0.008x |
|
Jamna Auto Industries Limited
NSE:JAMNAAUTO
|
0.273x |
|
GENERAL Elevator Co. Ltd.
SHE:300931
|
0.001x |
|
Guolin Environmental Tech Co Ltd
SHE:300786
|
0.001x |
Annual Cash Flow Conversion Efficiency for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Hubei Biocause Heilen Pharmaceutical Co. market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.27 Billion ≈ $332.64 Million |
CN¥7.55 Million ≈ $1.10 Million |
0.003x | -92.01% |
| 2024-12-31 | CN¥2.31 Billion ≈ $337.98 Million |
CN¥96.07 Million ≈ $14.06 Million |
0.042x | -28.48% |
| 2023-12-31 | CN¥2.36 Billion ≈ $344.86 Million |
CN¥137.06 Million ≈ $20.06 Million |
0.058x | -47.21% |
| 2022-12-31 | CN¥2.28 Billion ≈ $333.12 Million |
CN¥250.79 Million ≈ $36.70 Million |
0.110x | +97.51% |
| 2021-12-31 | CN¥2.22 Billion ≈ $325.26 Million |
CN¥123.98 Million ≈ $18.14 Million |
0.056x | -67.89% |
| 2020-12-31 | CN¥700.39 Million ≈ $102.49 Million |
CN¥121.67 Million ≈ $17.80 Million |
0.174x | -77.22% |
| 2019-12-31 | CN¥488.25 Million ≈ $71.45 Million |
CN¥372.33 Million ≈ $54.48 Million |
0.763x | +300.27% |
| 2018-12-31 | CN¥399.87 Million ≈ $58.51 Million |
CN¥76.18 Million ≈ $11.15 Million |
0.191x | +189.57% |
| 2017-12-31 | CN¥307.65 Million ≈ $45.02 Million |
CN¥-65.44 Million ≈ $-9.58 Million |
-0.213x | -- |
About Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including … Read more